Gabapentin (sold under the brand name Neurontin, among others) is a medication which is used to treat partial seizures, neuropathic pain, hot flashes, and restless legs syndrome. It is recommended as one of a number of first-line medications for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. About 15% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a measurable benefit. Gabapentin is taken by mouth.
Gabapentin has been shown to prevent epilepsy in various animal models, as well as in animal models of spasm, analgesia and amyotrophic lateral sclerosis. Gabapentin has a high affinity for novel junctions of brain tissue that can pass through some of the barriers in the body through amino acid transporters. Compared with other anticonvulsants, gabapentin has fewer behavioral and cardiovascular side effects. Gabapentin has a high affinity for novel junctions of brain tissue that can pass through some of the barriers in the body through amino acid transporters. Compared with other anticonvulsants, gabapentin has fewer behavioral and cardiovascular side effects. It is used for the treatment of patients with localized seizures, which cannot be satisfactorily controlled or tolerated by conventional antiepileptic drugs, and for the additional treatment of patients with localized seizures and subsequent systemic seizures.
Pharmacological effects:
The mechanism of gabapentin's anticonvulsive action is not clear, but animal studies suggest that gabapentin, similar to other anticonvulsant drugs on the market, can inhibit epileptic seizures. The results of the largest electrical shock tests in mice and rats, the benzothiazole seizure test, and other animal tests, such as an inherited epilepsy model, suggest gabapentin has antiepileptic effects, but the correlation between these models and the human body is unclear.
Gabapentin is structurally associated with the neurotransmitter GABA but does not interact with the GABA receptor, which is neither metabolized into a GABA or GABA agonist nor an inhibitor of GABA uptake or degradation. Radioactive ligand binding test found that gabapentin concentration reaches 100 microns, no affinity for many common receptor sites, including benzodiazepine receptors, glutamate receptor, NMDA receptor, quisqualate receptor, sea people oxalic acid receptors, his wooden turtle alkali - insensitivity or - sensitivity of amino acetic acid receptor, alpha 1, alpha 2 or beta receptors, adenosine A1 and A2 receptors, M and N receptors, D1 and D2 dopamine receptor, H1 receptor, serotonin S1 or S2 receptor, opioid mu, The voltage-sensitive calcium channel loci of the receptor or k receptor, the voltage-sensitive calcium channel loci of the nilodipine or diltiazem marker, and the voltage-sensitive sodium channel loci of the frog toxin A 20- peroxid-benzoate marker. Since the results of several commonly used trials to evaluate the effects of drugs on NMDA receptors are reversed, there is no unified understanding of gabapentin on NMDA receptors.
indications:
Refractory epilepsy. The combination of the anti-anxiety drug gabapentin and the antiviral drug valacyclovir has been reported to reduce the risk of acute postherpetic neuralgia.
Adverse reactions:
These include lethargy, vertigo, unsteady walking, and feeling of fatigue. These side effects are often seen in the early stages of medication. Most people can tolerate a small dose and a slow increase. Children are occasionally irritable and irritable, and disappear after drug withdrawal.
Usage:
Take 300 milligrams before bed for the first time. Add up to 300 milligrams a day later, up to 3,600 milligrams per day and take it three times.
Packing:1kg or other.
We can make powder become tablets or Injection if you want ,Ask our Sell talk detail.
